On Tuesday, Novavax delayed the start of a late-stage US trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.
The company said data from a separate phase 3 trial being conducted in Britain was expected by the first quarter of 2021 and could be the basis for regulatory approval.
Data from an early-to-mid stage or phase 2 trial of the vaccine is now expected on Friday, the company said. Early-stage data had showed the vaccine produced high levels of antibodies against the novel coronavirus.
The company is also preparing to deliver 100 million doses to the United States by January after it was awarded $1.6 billion for its potential vaccine and has also signed supply agreements with Canada and Japan.
